• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Business news
  • Information Letter on COVID-19

Information Letter on COVID-19

23 April 2020
Business news
Letter covid19

Our company is actively engaged in helping to find treatments and cures for COVID-19.

Dear Valued Customer,

While the COVID-19 crisis continues, I want to assure you that the PolyPeptide Group remains ready to support your business. Our sites are operating at almost-full capacity. At the same time, we have put numerous steps in place to protect the health and safety of our employees, including rigorous cleaning and infection control procedures.

Our company is also actively engaged in helping to find treatments and cures for COVID-19. Within the next few weeks, we will have teams at almost all sites working on projects to:

  1. Develop a peptide-based vaccine or vaccine cocktail against the virus
  2. Use peptides as immuno-modulators to allow our own immune system to fight this disease
  3. Use anti-inflammatory peptides to fight the excessive release of cytokines that this disease may cause
  4. Develop entry-inhibiting peptides that may inhibit coronavirus’ ability to enter human lung cells

We would be honored to help further your projects to combat the virus.

Our lines of communication remain open as we work to support your projects, your business, and your patients. Thank you for your ongoing partnership during this challenging time.

Wishing you and your family good health,

Kind regards,

 

Jane Salik, CEO

Download letter PDF here

Back to news

Related posts

24 April 2025

Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial


Read more
27 August 2024

Vinnova grant awarded to joint project between PolyPeptide and Red Glead Discovery for developing a more sustainable manufacturing method for a GLP-1 agonist.


Read more
8 May 2023

PolyPeptide launches new “Innovation Lab”


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers